Abstract

STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).

Links

PMC Free PDF

PMC Free Full Text

Authors

Hopkins CR

Institution

Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, United States.

Source

ACS chemical neuroscience 2:8 2011 Aug 17 pg 381

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22860166